System and Data Access Services a.System. Subject to the terms and conditions of this Addendum and solely for the purpose of providing access to Fund Data as set forth herein, State Street hereby agrees to provide the Fund, or certain third parties approved by State Street that serve as the Fund`s investment advisors, investment managers or fund accountants (the "Fund Accountants") or as the Fund`s independent auditors (the "Auditor"), with access to State Street`s Multicurrency HORIZONR Accounting System and the other information systems described in Attachment A (collectively, the "System") on a remote basis solely on the computer hardware, system software and telecommunication links described in Attachment B (the "Designated Configuration") or on any designated substitute or back-up equipment configuration consented to in writing by State Street, such consent not to be unreasonably withheld.
Know-How Transfer As and when required in relation to a COVID R&D Plan (and from time to time during the Term if new Know-How within the CureVac Know-How comes to be Controlled by CureVac) or as soon as reasonably practicable upon GSK’s request, CureVac shall disclose and/or deliver to GSK copies of all Development Data and the CureVac Know-How that is reasonably required for GSK’s Development activities in accordance with the COVID R&D Plan (including for regulatory purposes) (“Development Transfer Materials”), with the exception, however, of all Know-How comprised in the CureVac Manufacturing Technology which shall be made available to GSK or its designee as set forth in Section 5.2.1. The technology transfer to be undertaken under this Section 4.7 shall be overseen by the Joint Steering Committee. Any transfer of Know-How pursuant to this Section 4.7 shall be carried out on the basis of a specific technology transfer plan determined in good faith by the Parties and reflected in a technology transfer addendum to this Agreement, detailing at least the following activities together with appropriate timelines: (i) the provision by CureVac of soft copies and, to the extent reasonably required by GSK, hard copies of all Development Transfer Materials; (ii) the procurement by CureVac of the services of such qualified and experienced scientists and technicians, production and quality assurance personnel, engineers, and quality checking personnel as may be reasonably necessary to support the transfer of the Development Transfer Materials. Until completion of the transfer of the Development Transfer Materials, CureVac shall build and maintain a secure, readable, accessible and complete repository of the Development Transfer Materials.
Clinical Data and Regulatory Compliance The preclinical tests and clinical trials conducted by the Company, and to the knowledge of the Company, the preclinical tests and clinical trials conducted on behalf of or sponsored by the Company, that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures and all applicable laws and regulations, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, and 312; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectuses or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such Permits as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”) for the operation of the Company’s business as currently conducted, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules and regulations of the Regulatory Agencies except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
Data Access Services State Street agrees to make available to the Fund the Data Access Services subject to the terms and conditions of this Addendum and such data access operating standards and procedures as may be issued by State Street from time to time. The Fund shall be able to access the System to (i) originate electronic instructions to State Street in order to (a) effect the transfer or movement of cash or securities held under custody by State Street or (b) transmit accounting or other information (the transactions described in (i)(a) and (i)(b) above are referred to herein as “Client Originated Electronic Financial Instructions”), and (ii) access data for the purpose of reporting and analysis, which shall all be deemed to be Data Access Services for purposes of this Addendum.
Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.
Certain Additional Actions Regarding Intellectual Property If any Event of Default shall have occurred and be continuing, upon the written demand of the Collateral Agent, each Pledgor shall execute and deliver to the Collateral Agent an assignment or assignments of the registered Patents, Trademarks and/or Copyrights and Goodwill and such other documents as are necessary or appropriate to carry out the intent and purposes hereof. Within five (5) Business Days of written notice thereafter from the Collateral Agent, each Pledgor shall make available to the Collateral Agent, to the extent within such Pledgor’s power and authority, such personnel in such Pledgor’s employ on the date of the Event of Default as the Collateral Agent may reasonably designate to permit such Pledgor to continue, directly or indirectly, to produce, advertise and sell the products and services sold by such Pledgor under the registered Patents, Trademarks and/or Copyrights, and such persons shall be available to perform their prior functions on the Collateral Agent’s behalf.
Title Type of Work Registration No Registration Date Copyright Claimant Colorado Springs, CO, telephone directory, use through January 2007. Text TX0006336412 4/28/2006 Dex Media, Inc. Colville, WA, and surrounding area telephone directory, use through October 2007. Text TX0006444913 10/6/2006 Dex Media, Inc. Corvallis, CO, and surrounding area, alphabetical listings for Albany and surrounding area, use through Oct. 2007. Text TX0006483516 11/7/2006 Dex Media, Inc. Council Bluffs, IA & surrounding areas telephone directory, June 2007. Text TX0006399774 7/17/2006 Dex Media, Inc. Craig, CO, Meeker, Steamboat Springs telephone directory, use through August 2007. Text TX0006426721 8/30/2006 Dex Media, Inc. Davenport, IA, Bettendorf, Scott County telephone directory, use through October 2007. Text TX0006450386 11/7/2006 Dex Media, Inc. Decorah, IA, Elkader, West Union and surrounding area, telephone directory, use through January 2007. Text TX0006329602 4/27/2006 Dex Media, Inc. Denver, CO, covering the metro area (south) Plus telephone directory, use through December 2007. Text TX0006505993 2/2/2007 Dex Media, Inc. Denver, CO, covering the Metro area, telephone directory, use through December 2007. Text TX0006505955 2/2/2007 Dex Media, Inc. Denver, CO, metro area (east) telephone directory, use through December 2007. Text TX0006507709 2/2/2007 Dex Media, Inc. Denver, CO, metro area (west) telephone directory, use through December 2007. Text TX0006507708 2/2/2007 Dex Media, Inc. Des Moines, IA, and surrounding area, telephone directory, use through November 2007. Text TX0006493357 1/5/2007 Dex Media, Inc. Detroit Lakes, MI, telephone directory, use through 2007. Text TX0006357693 6/15/2006 Dex Media, Inc. Detroit Lakes, MN, and surrounding area, telephone directory, use through May 2006. Text TX0006309112 3/1/2006 Dex Media, Inc. Dex Plus-Twin Cities, MN, Minneapolis and surrounding area/Dex Plus-Twin Cities, St. Paul and surround area, use through April 2007. Text TX0006363132 5/17/2006 Dex Media, Inc. Dickinson, NC, telephone directory, February 2007. Text TX0006351989 4/28/2006 Dex Media, Inc. Dubuque, IA, telephone directory, use through September 2007. Text TX0006435132 10/6/2006 Dex Media, Inc. Durango, CO, Cortez, telephone directory, use through May 2007. Text TX0006357682 6/15/2006 Dex Media, Inc. East Central Minnesota, telephone directory, use through 2007. Text TX0006336347 4/27/2006 Dex Media, Inc. East County, OR, telephone directory, use through February 2007. Text TX0006319866 3/27/2006 Dex Media, Inc. East Tucson, AZ, area telephone directory, use through January 2007. Text TX0006299846 2/23/2006 Dex Media, Inc. East Valley, AZ, telephone directory, use through September 2007. Text TX0006449537 10/27/2006 Dex Media, Inc. East Valley PLUS, and surrounding area, use through September 2007. Text TX0006434775 10/6/2006 Dex Media, Inc. Eastern Montana, telephone directory, use through December 2007. Text TX0006538755 1/5/2007 Dex Media, Inc. Edina, MO, St. Louis Park, telephone directory, use through April 2007. Text TX0006346520 5/16/2006 Dex Media, Inc. Englewood, CO, Littleton, Centennial, Highlands Ranch, South Metro Denver, telephone directory, use through June 2007. Text TX0006399802 7/17/2006 Dex Media, Inc. Estes Park, Allenspark, Glen Haven and surrounding area, use through June 2007. Text TX0006372868 6/13/2006 Dex Media, Inc. Eugene, OR, Springfield, Lane County telephone directory, June 2007. Text TX0006369892 6/13/2006 Dex Media, Inc. Eugene/Springfield plus - use through June 2007. Text TX0006374163 6/13/2006 Dex Media, Inc. Evanston/Demmerer--and surrounding area, telephone directory, use through October 2007. Text TX0006455399 11/7/2006 Dex Media, Inc. Evergreen, CO, telephone directory, use through January 2007. Text TX0006336856 4/28/2006 Dex Media, Inc. Fargo, ND, Moorhead, telephone directory, use through March 2007. Text TX0006336418 4/27/2006 Dex Media, Inc. Faribault, MN, Owatonna telephone directory, use through October 2007. Text TX0006450301 11/7/2006 Dex Media, Inc. Farmington, NM, Aztec, Blanco & others, telephone directory, use through February 2007. Text TX0006337696 4/28/2006 Dex Media, Inc. Fergus Falls, MN, telephone directory, use through September 2007. Text TX0006450380 11/7/2006 Dex Media, Inc. Flagstaff, AZ, and surrounding area, telephone directory, use through May 2007. Text TX0006342725 5/31/2006 Dex Media, Inc. Annex 3 to Guarantee and Collateral Agreement
Data Access and Proprietary Information 6.1 The Fund acknowledges that the databases, computer programs, screen formats, report formats, interactive design techniques, and documentation manuals furnished to the Fund by the Transfer Agent as part of the Fund’s ability to access certain Fund Confidential Information maintained by the Transfer Agent on databases under the control and ownership of the Transfer Agent or other third party (“Data Access Services”) constitute copyrighted, trade secret, or other proprietary information of substantial value to the Transfer Agent or other third party (collectively, “Transfer Agent Proprietary Information”). In no event shall Transfer Agent Proprietary Information be deemed Fund Confidential Information. The Fund agrees to treat all Transfer Agent Proprietary Information as proprietary to the Transfer Agent and further agrees that it shall not divulge any Transfer Agent Proprietary Information to any person or organization except as may be provided hereunder. Without limiting the foregoing, the Fund agrees for itself and its employees and agents to:
Data Transfer Optionee explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of Optionee’s personal data as described in this document by and among, as applicable, the Employer, and the Company and its Subsidiaries and Affiliates for the exclusive purpose of implementing, administering and managing Optionee’s participation in the Plan. Optionee understands that the Company, its Affiliates, its Subsidiaries and the Employer hold certain personal information about Optionee, including, but not limited to, name, home address and telephone number, date of birth, social security number (or other identification number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all options or any other entitlement to shares of stock awarded, canceled, purchased, exercised, vested, unvested or outstanding in Optionee’s favor for the purpose of implementing, managing and administering the Plan (“Data”). Optionee understands that the Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in Optionee’s country or elsewhere and that the recipient country may have different data privacy laws and protections than Optionee’s country. Optionee may request a list with the names and addresses of any potential recipients of the Data by contacting the Stock Plan Administrator. Optionee authorizes the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing Optionee’s participation in the Plan, including any requisite transfer of such Data, as may be required to a broker or other third party with whom Optionee may elect to deposit any Shares acquired upon the exercise of this Option. Optionee understands that Data will be held only as long as is necessary to implement, administer and manage participation in the Plan. Optionee may, at any time, view Data, request additional information about the storage and processing of the Data, require any necessary amendments to the Data or refuse or withdraw the consents herein, in any case without cost, by contacting the Stock Plan Administrator in writing. Optionee understands that refusing or withdrawing consent may affect Optionee’s ability to participate in the Plan. For more information on the consequences of refusing to consent or withdrawing consent, Optionee may contact the Stock Plan Administrator at the Company.
Transfer of Know-How To facilitate Licensee’s accomplishment of the responsibilities set forth in Section 4.01 above, within thirty (30) days of the Effective Date of this Agreement GenuPro shall in good faith supply Licensee with copies of the GenuPro Know-How, Lilly Know-How and Lilly Manufacturing Know-How pertinent to the development of the GenuPro Compound in the Field that GenuPro is able to provide using commercially reasonable efforts and which is in the possession of GenuPro on the Effective Date, and shall transfer to Licensee the legal title to any IND on the GenuPro Compound presently on file in GenuPro’s name with the FDA and any comparable filings in other countries of the Territory. GenuPro shall also facilitate transfer of GenuPro Compound manufacturing-related information (including any associated quality and analytical information) to Licensee from those Third Parties from which GenuPro or PPD has received quotations for manufacturing GenuPro Compound that GenuPro is not under any obligation to keep confidential from a third party. GenuPro will provide Licensee with all relevant information available and known to GenuPro or PPD concerning the safety, handling, use, disposal and environmental effects of the GenuPro Compound or as may be useful to Licensee to conduct the Project, including but not limited to any communications with regulatory agencies. [*] Confidential treatment requested; certain information omitted and filed separately with the SEC.
